Výsledky vyhľadávania - "Letrozole therapeutic use"

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates

Autori: Chang Gon Kim Min Hwan Kim Jee Hung Kim a ďalší

Prispievatelia: Chang Gon Kim Min Hwan Kim Jee Hung Kim a ďalší

Zdroj: Breast Cancer Res
Breast Cancer Research, Vol 25, Iss 1, Pp 1-16 (2023)

Predmety: Lymphocytes / metabolism, 0301 basic medicine, Neutrophils, Receptor, ErbB-2, Breast Neoplasms, Palbociclib, CDK4/6 inhibitor, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Humans, Lymphocytes, Breast Neoplasms* / metabolism, Neutrophil-to-lymphocyte ratio, RC254-282, Retrospective Studies, Letrozole / therapeutic use, Research, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neutrophils / metabolism, 3. Good health, ErbB-2 / metabolism, Letrozole, Advanced breast cancer, Female, Receptor

Popis súboru: application/pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36635767
https://doaj.org/article/93318bd67f0041e39e14dac885e50ca8

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Autori: Ruhstaller, T. Giobbie-Hurder, A. Colleoni, M. a ďalší

Prispievatelia: Ruhstaller, T. Giobbie-Hurder, A. Colleoni, M. a ďalší

Predmety: Aged, Antineoplastic Agents, Hormonal/administration & dosage, Hormonal/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/metabolism, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Female, Humans, Letrozole/administration & dosage, Letrozole/adverse effects, Letrozole/therapeutic use, Middle Aged, Postmenopause, Receptors, Estrogen/metabolism, Progesterone/metabolism, Tamoxifen/administration & dosage, Tamoxifen/adverse effects, Tamoxifen/therapeutic use

Relation: Journal of Clinical Oncology; https://iris.unil.ch/handle/iris/199420; serval:BIB_D4E4E78E667C; 000456131200003

Dostupnosť: https://iris.unil.ch/handle/iris/199420
https://doi.org/10.1200/JCO.18.00440

A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

Autori: Niu, Nan Qiu, Fang Xu, Qianshi a ďalší

Zdroj: Nat Commun
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)

Predmety: Humans, Female, Letrozole, Ki-67 Antigen, Receptor, ErbB-2, Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors, Neoadjuvant Therapy, Breast Neoplasms, Breast Neoplasms/pathology, Protein Kinase Inhibitors/therapeutic use, Science, Receptor, ErbB-2/metabolism, Oncologie, General Physics and Astronomy, Sciences de la santé humaine, General Biochemistry, Genetics and Molecular Biology, Article, Physics and Astronomy (all), 03 medical and health sciences, 0302 clinical medicine, Letrozole/therapeutic use, pyrotinib, Human health sciences, Biochemistry, Genetics and Molecular Biology (all), Multidisciplinary, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Neoadjuvant Therapy/methods, Chemistry (all), General Chemistry, Receptor, ErbB-2/genetics, 3. Good health, Oncology

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36396665
https://doaj.org/article/1d9c37ba0fbf4148af08531c29508fb7

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer:analysis from a nationwide phase II DBCG trial

Autori: Skriver, Signe Korsgaard Jensen, Maj-Britt Knoop, Ann Soegaard a ďalší

Zdroj: Skriver , S K , Jensen , M-B , Knoop , A S , Ejlertsen , B & Laenkholm , A-V 2020 , ' Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer : analysis from a nationwide phase II DBCG trial ' , Breast cancer research : BCR , vol. 22 , no. 1 , 46 . https://doi.org/10.1186/s13058-020-01285-8

Predmety: Aged, 80 and over, Antineoplastic Agents/therapeutic use, Biomarkers, Tumor/metabolism, Breast Neoplasms/drug therapy, Carcinoma, Ductal, Breast/drug therapy, Lobular/drug therapy, Female, Follow-Up Studies, Humans, Letrozole/therapeutic use, Lymphocytes, Tumor-Infiltrating/drug effects, Middle Aged, Neoadjuvant Therapy, Prognosis, Receptor, ErbB-2/metabolism, Receptors, Estrogen/metabolism, Progesterone/metabolism

Popis súboru: application/pdf

Dostupnosť: https://researchprofiles.ku.dk/da/publications/b254dec4-9a17-45bb-b2ee-6c47fb429ba1
https://doi.org/10.1186/s13058-020-01285-8
https://curis.ku.dk/ws/files/251311995/s13058_020_01285_8_1.pdf

Letrozole should be the first-choice drug for women with anovulatory subfertility in Denmark / Letrozol bör vaere förstevalgspræparat til kvinder med anovulatorisk subfertilitet i Danmark

Autori: Hedegaard, Morten

Zdroj: Ugeskrift for Laeger. 181(18):1680